Lupin launches respiratory device InspiraChamber in US

Lupin Limited, through its US subsidiary Lupin Pharmaceuticals Inc, has launched new InspiraChamber anti-static valved holding chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc. The agreement grants Lupin exclusive rights to promote, distribute and market InspiraChamber VHC in the US.
 
Asthma medicines are grouped into several categories according to treatment type, including quick-relief/rescue and long-term control. Young children and the elderly may have difficulty taking these medications, due to difficulty administering them via pressurised metered-dose inhalers.
 
Valved holding chambers (VHCs) make it easier for these people to take their medicines Developed by InspiRX, the new InspiraChamber VHC is a device that has been designed to enhance delivery of aerosol therapies. The InspiraChamber VHC is intended to be used by patients who are under the care or treatment of a physician or licensed healthcare professional. The device is intended to be used by these patients to administer aerosolised medication from most pressurised metered dose inhalers (pMDIs). “Several clinical and laboratory studies have shown that the InspiraChamber VHC has features that are superior to the leading VHCs in the market. These features may lead to more effective delivery of asthma medicines,” said Lupin in a press release.
 
The InspiraChamber VHC launch strengthens Lupin existing brand portfolio in the US. Key prescribers for InspiraChamber will include pediatricians and primary care physicians which are strategic customer groups for Lupin already, so we are well positioned to capitalise on this opportunity. Lupin’s current brands sales force will promote InspiraChamber in the US market and the product will be marketed along with other Lupin brands, including Suprax, Alinia for oral suspension, Locoid lotion and Antara.
 
“The launch of InspiraChamber VHC demonstrates Lupin’s commitment to grow its brand franchise in the US and bring meaningful products to patients in the country. The launch also heralds Lupin’s entry into the larger US inhalation and related markets.” said Vinita Gupta, CEO, Lupin Limited.
 
Michael Amato, CEO, InspiRx Inc, said, “The agreement enables the commercialisation of InspiraChamber in the US. Furthermore, and given Lupin’s brand equity within the US paediatric community, the launch ensures that the product reaches children, infants and toddlers - an age demographic which we feel needs a product like InspiraChamber; a VHC that ensures better and more effective drug delivery.”